Relief Therapeutics Holding SA (SWX: RLF)

Market Cap	54.68M
Revenue (ttm)	8.60M
Net Income (ttm)	-46.24M
Shares Out	12.54M
EPS (ttm)	-3.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	90,934
Open	4.300
Previous Close	4.360
Day's Range	3.750 - 4.300
52-Week Range	1.055 - 7.600
Beta	-14.74
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 1, 2025

About RLF

Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting; OLPRUVA, a sodium phenylbutyrate for the treatment of urea cycle disor...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 49
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: RLF

Financial Performance

In 2023, RLF's revenue was 6.03 million, a decrease of -0.79% compared to the previous year's 6.08 million. Losses were -98.18 million, 93.3% more than in 2022.